Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecemotide vs placebo after chemoradiotherapy in unresectable stage III NSCLC
2013-003760-30Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tecemotide with Placebo (2 arms). Primary endpoint: Overall survival. Started Feb 2014; status: completed.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-003760-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003760-30.